May 27, 2025 — CeleCor Therapeutics has successfully completed a Phase 3 clinical trial of its investigational heart attack drug, DisaggproT (zalunfiban), marking a potential breakthrough in emergency cardiac care. The drug is designed for rapid use at the first point of medical contact—even before patients reach the hospital.
The international study, named the CeleBrate trial, evaluated Disaggpro in patients suffering from ST-elevation myocardial infarction (STEMI)—the most serious type of heart attack. STEMI occurs when a blood clot completely blocks blood flow to part of the heart. In such cases, restoring blood flow quickly is critical to avoid death or permanent heart damage.
“This trial shows that the future of STEMI treatment lies in delivering care as soon as the diagnosis is made, even outside the hospital,” said Professor Arnoud WJ Van ’t Hof, M.D., Ph.D., principal investigator of the CeleBrate trial and head of interventional cardiology at Maastricht University Medical Center and Zuyderland Medical Center in the Netherlands. “This third-generation glycoprotein IIb/IIIa blocker could be a game changer.”
With patient enrollment now complete, researchers will unblind and analyze the data. Final results are expected in the third quarter of 2025. The findings will be shared at a major medical conference and submitted for publication. If results are positive, CeleCor plans to file for marketing approval with global regulatory agencies.
“In heart attacks, every minute counts. The longer the artery stays blocked, the higher the risk of death or heart damage,” said Dr. C. Michael Gibson, president and CEO of the Baim Institute for Clinical Research and professor of medicine at Harvard Medical School. “If we can start treatment immediately, we can save lives and improve patient outcomes.”
While hospital care for heart attacks has improved over the last three decades, about half of all heart attack deaths still occur before the patient arrives at the hospital. Disaggpro is made to address that gap. It is delivered through a simple under-the-skin injection, takes effect within 10 to 15 minutes, and has a short half-life of about one hour. This fast action keeps blood flowing in the early, critical minutes and doesn’t interfere with later treatments like stenting or surgery.
“Disaggpro was designed to stop platelets from clumping and forming clots in the first minutes after a heart attack begins,” said Dr. Barry Coller, who invented the drug. He is vice president for medical affairs and physician-in-chief at The Rockefeller University. “Importantly, the drug wears off within two hours—just as hospital cardiologists are opening the blocked artery using a balloon and stent.”
If approved, Disaggpro could become a key tool for first responders and emergency departments, helping treat heart attacks earlier and more effectively than ever before.
Related topics:
